Relmada Therapeutics Announces Participation in Goldman Sachs 42nd Annual Global Healthcare Conference
Relmada Therapeutics, Inc. (Nasdaq: RLMD) announced that CEO Sergio Traversa will participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 8:00 a.m. Eastern Time. Interested parties can access a live webcast of the event through the company's website, where an archived replay will be available for one year. Relmada focuses on major depressive disorder (MDD) and is advancing its lead program, REL-1017, a novel NMDA receptor channel blocker, currently in late-stage development.
- CEO's participation in a significant healthcare conference could enhance visibility and investor interest.
- Relmada is focusing on late-stage development of REL-1017, which may position the company favorably in the CNS market.
- None.
NEW YORK, June 7, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer of Relmada, is scheduled to participate in a fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Thursday, June 10, 2021at 8:00 a.m. Eastern Time.
Participants may access a live webcast of the event through the following link: https://kvgo.com/gs-global-healthcare/relmada-therapeutics-inc-june-2021
The webcast can also be accessed in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar. An archived replay of the event will be available for one year after the conclusion of the presentation.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com.
Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding the expected use of the proceeds from the offering. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to," "potential," "promising," and similar expressions. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the risk factors described under the heading "Risk Factors" set forth in the Company's reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
Tim@LifeSciAdvisors.com
Media Inquiries:
FischTank PR
Relmada@FischTankPR.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-announces-participation-in-goldman-sachs-42nd-annual-global-healthcare-conference-301306512.html
SOURCE Relmada Therapeutics, Inc.
FAQ
When is Relmada Therapeutics scheduled to speak at the Goldman Sachs Healthcare Conference?
How can I access the webcast of Relmada's Goldman Sachs Conference presentation?
What is the focus of Relmada Therapeutics?
What is REL-1017 and its significance?
